MedTrace Logo

A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus

NCT02501161 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1012

Last updated 2019-11-27

Study results available
· View outcomes & findings →

Summary

This trial is conducted in Africa, Asia, Europe, North America and South America. The purpose is to compare long-term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) in insulin naïve subjects with type 2 diabetes mellitus inadequately controlled with oral anti diabetics.

Conditions

Interventions

DRUG

insulin degludec/liraglutide

Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.

DRUG

insulin glargine

Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry GCR, 1452 · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2018-10-03
Completion
2018-10-03

Countries

  • United States
  • Argentina
  • Brazil
  • Czechia
  • Hungary
  • India
  • Israel
  • Italy
  • Mexico
  • Norway
  • Poland
  • Russia
  • Slovakia
  • South Africa
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02501161 on ClinicalTrials.gov